Reduction of leptin levels by four cardiac hormones: Implications for hypertension in obesity

Experimental and Therapeutic Medicine

Volumn 6, Issue 2, 2013, Pages 611-615

  Lane, Meghan L ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cardiac hormones; Hypertension in obesity; Hypothalamus; Leptin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; KALIURETIC PEPTIDE; LEPTIN; LONG ACTING NATRIURETIC PEPTIDE; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPERTENSION; HYPOTHALAMUS; OBESITY;

EID: 84879661364     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1173     Document Type: Article

References (41)

1. Kshatriya S, Lui K, Salah A, Szombathy T, Freeman RH, Reams GP, Spear RM and Villarreal D: Obesity hypertension: the regulatory role of leptin. Int J Hypertens 2011: 270624, 2011.
2. Lönnqvist F: The obese (ob) gene and its product leptin-a new route toward obesity treatment in man? QJ Med 89: 327-332, 1996.
3. Misra A and Garg A: Leptin, its receptor and obesity. J Investig Med 44: 540-548, 1996.
4. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, et al: Identification and expression cloning of a leptin receptor, OB-R. Cell 83: 1263-1271, 1995.
5. Esler M, Vaz M, Collier G, Nester P, Jennings G, Kaye D, Seals D and Lambert G: Leptin in human plasma is derived in part from the brain, and cleared by the kidneys. Lancet 351: 879-880, 1998.
6. Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, Hastings J, Socratous F and Esler M: Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab 286: E774-E752, 2004.
7. Morash B, Li A, Murphy PR, Wilkinson M and Ur E: Leptin gene expression in the brain and pituitary gland. Endocrinology 140: 5995-5998, 1999.
8. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL and Caro JF: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med 334: 292-295, 1996.
9. Garrison RJ, Kannel WB, Stokes J III and Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16: 235-251, 1987.
10. Wofford MR and Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 10: 3621-3637, 2004.
11. Shek EW, Brands MW and Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 31: 409-414, 1998.
12. Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ, Park BH and Kim SH: Leptin reduces plasma ANP level via nitric oxide-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 298: R1007-R1016, 2010.
13. Huang F, Xiong X, Wang H, You S and Zeng H: Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-kappaB. Acta Biochim Biophys Sin (Shanghai) 42: 325-331, 2010.
14. Sengenès C, Berlan M, De Glisezinski I, Lafontan M and Galitzky J: Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14: 1345-1351, 2000.
15. Sengenès C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M and Galitzky J: Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278: 48617-48626, 2003.
16. Moro CC, Galitzky J, Sengenès C, Crampes F, Lafontan M and Berlan M: Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther 308: 984-992, 2004.
17. Uehlinger DE, Weidemann P, Gnädinger MP, Hasler L, Bachmann C, Shaw S, Hellmüller B and Lang RE: Increase in circulating insulin induced by atrial natriuretic peptide in normal humans. J Cardiovasc Pharmacol 8: 1122-1129, 1986.
18. Galitzky J, Sengenès C, Thalamus C, Marques MA, Senard JM, Lafontan M and Berlan M: The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 42: 536-544, 2001.
19. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M and Jordan J: Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90: 3622-3628, 2005.
20. Vesely DL: Natriuretic hormones. In: Seldin and Giebisch's, The Kidney: Physiology and Pathophysiology. Alpern RJ, Moe OW and Caplan M (eds). 5th edition. Elsevier/North-Holland Biomedical Press, Amsterdam, pp1241-1281, 2013.
21. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 258: F1401-F1408, 1990.
22. + transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2. J Clin Invest 89: 1411-1417, 1992.
23. Benjamin BA and Peterson TV: Effects of proANF-(31-67) on sodium excretion in conscious monkeys. Am J Physiol 269: R1351-R1355, 1995.
24. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 22: 121-124, 1995.
25. Villarreal D, Reams GP, Taraben A and Freeman RH: Hemodynamic and renal effects of proANF31-67 in hypertensive rats. Proc Soc Exp Biol Med 221: 166-170, 1999.
26. Dietz JR, Scott DY, Landon CS and Nazian SJ: Evidence supporting a physiological role for proANP-(1-30) in the regulation of renal excretion. Am J Physiol Regul Integr Comp Physiol 280: R1510-R1517, 2001.
27. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G and Schocken DD: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 90: 1129-1140, 1994.
28. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G and Schocken DD: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 78: 1128-1134, 1994.
29. Vesely DL, Dietz JR, Parks JR, Baig M, McCormick MT, Cintron G and Schocken DD: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 98: 323-329, 1998.
30. Sugarawa A, Nakao K, Sakamoto M, Morii N, Yamada T, Itoh H, Shiono S and Imura H: Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet 2: 1426-1427, 1985.
31. Arendt R, Gerbes A, Ritter D, Stangl E and Zähringer J: Atrial natriuretic factors in plasma of patients with arterial hypertension, heart failure or cirrhosis of the liver. J Hypertens Suppl 4: S131-S135, 1986.
32. McMurray RW Jr and Vesely DL: Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Metabolism 38: 1231-1237, 1989.
33. McMurray RW Jr and Vesely DL: Weight reduction decreases the circulating concentration of the N-terminus of the ANF prohormone. Am J Med Sci 303: 2-8, 1992.
34. McMurray RW Jr and Vesely DL: Calorie-restricted weight reduction, blood pressure, and atrial natriuretic peptides. Nutrition 9: 178-182, 1993.
35. Cao R, Brakenhielm E, Wahlestedt C, Thyberg J and Cao Y: Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci USA 98: 6390-6395, 2001.
36. Nguyen JP, Frost CD, Lane ML, Skelton lv WP, Skelton M and Vesely DL: Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor. Eur J Clin Invest 42: 1061-1067, 2012.
37. Fain JN, Kanu A, Bahouth SW, Gowan GS and Lloyd Hiler M: Inhibition of leptin release by atrial natriuretic peptide (ANP) in human adipocytes. Biochem Pharmacol 65: 1883-1888, 2003.
38. Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E and Rappelli A: Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 19: 581-585, 1996.
39. Vesely DL: Peptides from the N-terminus of the atrial natriuretic factor prohormone enhance guanylate cyclase activity and increase cyclic GMP levels in a wide variety of tissues. Mol Cell Biochem 109: 43-50, 1992.
40. Jensen MD, Haymond MW, Rizza RA, Cryer PE and Miles JM: Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 80: 1168-1173, 1989.
41. Bougnères P, Stunff CL, Pecqueur C, Pinglier E, Adnot P and Ricquier D: In vivo resistance of lipolysis to epinephrine. A new feature of childhood onset obesity. J Clin Invest 99: 2568-2573, 1997.